We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 Top Growth Plays That Could Smash The FTSE 100: ARM Holdings plc, GlaxoSmithKline plc & Diageo plc

Though the FTSE 100 (INDEXFTSE:UKX) could go much higher, ARM Holdings plc (LON:ARM), GlaxoSmithKline plc (LON:GSK) & Diageo plc (LON:DGE) could beat it.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

FTSE100

With the S&P 500 hitting record highs, 2014 has been something of a disappointment for the FTSE 100. Indeed, the index is up just 1% since the turn of the year, but does seem to have huge potential over the medium term. That’s because it trades on a price to earnings (P/E) ratio of just 13.8 and has a yield of around 3.5% — both of which indicate that the index could push northwards.

Should you buy Diageo Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

However, here are three shares that despite the FTSE 100’s potential, could still outperform the UK’s main index.

ARM

Although shares in ARM (LSE: ARM) have fallen by 12% during the course of 2014, the intellectual property business could beat the FTSE 100 going forward. That’s because it offers investors a vast amount of growth potential, with the company’s earnings per share (EPS) expected to increase by an impressive 23% in 2015. Furthermore, with shares in ARM having fallen, they now represent much better value for money. Indeed, although ARM’s price to earnings (P/E) ratio remains high at 41.5, its price to earnings growth (PEG) ratio of just 1.5 means that it could outperform the FTSE 100 over the medium term.

GlaxoSmithKline

As with ARM, 2014 has been a tough year for GlaxoSmithKline (LSE: GSK). Its shares have dropped by 9% and the company continues to suffer from weak sentiment due to bribery allegations. However, GlaxoSmithKline also has a highly diversified and capable drugs pipeline that has the potential to deliver brisk earnings growth in future years. Certainly, all drug pipelines come with a large dollop of uncertainty, but GlaxoSmithKline appears to have a well-balanced pipeline that should benefit from a renewed focus by the company after the sale of its consumer brands. In the meantime, a yield of 5.6% should help to push investors’ total return above that of the FTSE 100.

Diageo

Diageo (LSE: DGE) is also down in 2014, with the alcoholic beverages company seeing its share price fall by 12% year-to-date. However, demand for premium alcoholic drinks should remain robust in the long run – even if the world economy does fall back into negative growth territory. Moreover, Diageo’s strong stable of brands should ensure that demand for its products remains buoyant in developed nations, while emerging markets such as China and India present a huge opportunity for the company to increase its sales and profitability. As a result, it could have a much brighter future and has the scope to beat the main index moving forward.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Not sure what a SIPP is? 3 reasons it could pay to know!

Christopher Ruane digs into some of the details of a SIPP and highlights a trio of possible benefits he sees…

Read more »

Investing Articles

Lloyds shares have done nothing for almost half a year — are they stuck at £1?

Mark Hartley takes a closer look at why his Lloyds' shares have barely moved in 2026, but finds reassurance in…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Forget waiting for the IPOs: here’s how to invest in SpaceX and Anthropic today

SpaceX and Anthropic IPOs in 2026 are going to be huge. But investors don’t need to wait for them to…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

2 FTSE investment trusts to consider for passive income in 2026

Ben McPoland spotlights a pair of struggling investment trusts, one of which has crashed 50%. Why does he think they…

Read more »

Tesla car at super charger station
Investing Articles

How much impact could a SpaceX merger have on the Tesla share price?

A SpaceX IPO could be the biggest in history and if Musk's merger plans go ahead, it could save the…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£5,000 invested in Greggs shares 2 years ago is now worth…

Greggs' shares have been a diabolical investment over the last two years. But could they offer value today given they’ve…

Read more »

Investing Articles

Down 26% this year! Should I keep buying shares in this UK growth company?

Is Judges Scientific still one of the UK’s top growth shares? Stephen Wright thinks it might be – despite a…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 income shares really turn £20,000 into £119,162?

James Beard explains how reinvesting dividends from income shares could create huge long-term wealth, including for those investors starting later…

Read more »